Global Systemic Scleroderma Treatment Market by Drug Class (Endothelin Receptor Antagonist, Immunosuppressors, Prostacyclin Analogues, PDE-5 Inhibitors) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global systemic scleroderma market was valued at USD1.4 billion in 2019. It is projected to grow at a compound annual rate (CAGR of 4.0%) between 2020 and 2027. Market growth is expected to be driven by the availability of new therapies and supplemental approvals for existing treatments. Systemic scleroderma treatment's market is driven primarily by off-label drug use for its symptomatic indications, such as rheumatoid. The lack of cures and the high use of off-label drugs are two of the main reasons rare disease markets are so popular. This will drive the development of small-molecule combination therapies and targeted biologics.
Sponsors and researchers are working together to develop novel candidates quickly. The types and mechanisms of these pipeline products are varied. Kadmon Holdings, Inc. was granted Orphan Drug Designation (US FDA) in September 2020 for its novel drug candidate, Belumosudil, which is designed to treat systemic sclerosis. Belumosudil, (KD025), is a Rho -associated coiled coil kinase 2 with a dual mechanism for treating both immune and fibric components. It is currently in phase 2 clinical trials.
The market for systemic Sclerosderma treatment is not growing because of a lack of validated results and unique challenges in drug development. This disease condition is currently facing a challenge in drug development due to recent clinical trial failures. In September 2020, Corbus Pharmaceuticals Holdings Inc.'s pipeline product Lenabasum failed both primary and secondary endpoints, despite promising results from phase 2 clinical trials.
This disease is often accompanied by other conditions that require the use of multiple drug classes to treat the condition. Pulmonary arterial hypertension (PAH), was the most popular. This comorbidity can be treated with multiple drugs and branded drugs.
Drug Class Insights
The market for systemic skin scleroderma treatment was dominated by the immunosuppressors category, accounting for 64.2% of the total revenue in 2019. There is no cure for this condition, so a wide range of drugs are used to provide symptoms relief. Immunosuppressants are the most prominent, as they contain several biologics from well-known players like Roche. This segment is a rapidly growing one, and there are many pipeline drugs for systemic skin scleroderma.
Industry growth is expected to be fueled by the introduction of new products on the market for treatment of systemic scleroderma. This will be accompanied with a strong product pipeline. The U.S. FDA approved Boehringer Ingelheim International GmbH’s product - Ofev, (nintedanib), for the treatment of patients with Systemic Sclerosis with Interstitial Lung Disease. This was followed by the EMA's approval in April 2020. In addition, new therapies such as ziritaxestat and nilotinib are expected to be available within the timeframe that is classified under "other drug classes".
Over the forecast period, PDE-5 inhibitors is expected to expand. To expand their customer base, companies are focusing on label extension. In June 2020, Pfizer Inc. reported that phase 3 clinical trials for Revatio were completed. ERAs are still in focus because this class of drugs includes branded therapies mainly due to their use for the treatment of high-incidence indications, i.e. PAH.
Regional Insights
North America was the dominant market for systemic scleroderma treatments in 2019, accounting for 42.9% of the total revenue. The penetration of biologics in developing regions is increasing. The key driver of revenue is access to immunosuppressants that have been recently developed and a favorable reimbursement situation.
The United States has an average of 20 cases per million people with systemic scleroderma and 276 cases per million with systemic sclerosis. The total healthcare costs for patients ranged from USD 17,365 to USD 18,396. Systemic scleroderma treatment is growing because of the steady increase in the number of patients.
Europe has a smaller share than the U.S. due to a higher usage of generics and Biosimilars for offlabel treatment systemic scleroderma. The U.K. market for systemic skin disease treatment is expected to grow significantly over the forecast period. This is due to the introduction of small molecules and biologics for the treatment and indications of systemic inflammation. Actelion Pharmaceuticals Ltd., a subsidiary Johnson and Johnson Services, Inc., has announced that Uptravi was approved by the EMA for treatment of Pulmonary Arterial hypertension.
Generics and OTC medications are the most common treatment for scleroderma in developing countries. Japan's market for systemic treatment of scleroderma is seeing price reductions and faster access to new orphan treatments. Growth in Latin America and the MEA will be driven by an increase in access to generic and biosimilar immunosuppressants.
Market Share Insights & Key Companies
There are significant opportunities for growth in the market for systemic skin cancer treatment. To increase their market share, pharmaceutical companies are pursuing strategies like mergers and acquisitions or partnerships. Janssen Pharmaceutical, a Johnson and Johnson Services, Inc. company, acquired Actelion Pharmaceuticals Ltd. in 2017 to become the biggest player in the field pulmonary hypertension.
There is an underlying factor: a preference for immunosuppressants when treating scleroderma induced ILD and PAH. These therapies will continue to be popular until new curatives are developed. This is due to the increased penetration of the class of drugs and their superior efficacy compared with the existing options - methotrexate and cyclophosphamide - The following are some of the major players in the market for systemic scleroderma treatments:
-
Boehringer Ingelheim International GmbH
-
Gilead Sciences Inc.
-
GlaxoSmithKline plc
-
Novartis AG
-
Pfizer Inc.
-
Bayer AG
Up Market Research published a new report titled “Systemic Scleroderma Treatment Market research report which is segmented by Drug Class (Endothelin Receptor Antagonist, Immunosuppressors, Prostacyclin Analogues, PDE-5 Inhibitors), By Players/Companies Novartis AG, Gilead Sciences Inc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Pfizer Inc, Bayer AG”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Systemic Scleroderma Treatment Market Research Report |
| By Drug Class | Endothelin Receptor Antagonist, Immunosuppressors, Prostacyclin Analogues, PDE-5 Inhibitors |
| By Companies | Novartis AG, Gilead Sciences Inc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Pfizer Inc, Bayer AG |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 227 |
| Number of Tables & Figures | 159 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Systemic Scleroderma Treatment Market Report Segments:
The market is segmented by Drug Class (Endothelin Receptor Antagonist, Immunosuppressors, Prostacyclin Analogues, PDE-5 Inhibitors).
Systemic Scleroderma Treatment Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Systemic Scleroderma Treatment Market
Overview of the regional outlook of the Systemic Scleroderma Treatment Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Systemic Scleroderma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Systemic Scleroderma Treatment Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Endothelin Receptor Antagonist
2. Immunosuppressors
3. Prostacyclin Analogues
4. PDE-5 Inhibitors
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Scleroderma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Systemic Scleroderma Treatment Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Scleroderma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Scleroderma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Scleroderma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Scleroderma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Scleroderma Treatment Market Size & Forecast, 2018-2028
4.5.1 Systemic Scleroderma Treatment Market Size and Y-o-Y Growth
4.5.2 Systemic Scleroderma Treatment Market Absolute $ Opportunity
Chapter 5 Global Systemic Scleroderma Treatment Market Analysis and Forecast by Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug Class
5.1.2 Basis Point Share (BPS) Analysis by Drug Class
5.1.3 Absolute $ Opportunity Assessment by Drug Class
5.2 Systemic Scleroderma Treatment Market Size Forecast by Drug Class
5.2.1 Endothelin Receptor Antagonist
5.2.2 Immunosuppressors
5.2.3 Prostacyclin Analogues
5.2.4 PDE-5 Inhibitors
5.3 Market Attractiveness Analysis by Drug Class
Chapter 6 Global Systemic Scleroderma Treatment Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Systemic Scleroderma Treatment Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Systemic Scleroderma Treatment Analysis and Forecast
8.1 Introduction
8.2 North America Systemic Scleroderma Treatment Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Systemic Scleroderma Treatment Market Size Forecast by Drug Class
8.6.1 Endothelin Receptor Antagonist
8.6.2 Immunosuppressors
8.6.3 Prostacyclin Analogues
8.6.4 PDE-5 Inhibitors
8.7 Basis Point Share (BPS) Analysis by Drug Class
8.8 Absolute $ Opportunity Assessment by Drug Class
8.9 Market Attractiveness Analysis by Drug Class
Chapter 9 Europe Systemic Scleroderma Treatment Analysis and Forecast
9.1 Introduction
9.2 Europe Systemic Scleroderma Treatment Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Systemic Scleroderma Treatment Market Size Forecast by Drug Class
9.6.1 Endothelin Receptor Antagonist
9.6.2 Immunosuppressors
9.6.3 Prostacyclin Analogues
9.6.4 PDE-5 Inhibitors
9.7 Basis Point Share (BPS) Analysis by Drug Class
9.8 Absolute $ Opportunity Assessment by Drug Class
9.9 Market Attractiveness Analysis by Drug Class
Chapter 10 Asia Pacific Systemic Scleroderma Treatment Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Systemic Scleroderma Treatment Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Systemic Scleroderma Treatment Market Size Forecast by Drug Class
10.6.1 Endothelin Receptor Antagonist
10.6.2 Immunosuppressors
10.6.3 Prostacyclin Analogues
10.6.4 PDE-5 Inhibitors
10.7 Basis Point Share (BPS) Analysis by Drug Class
10.8 Absolute $ Opportunity Assessment by Drug Class
10.9 Market Attractiveness Analysis by Drug Class
Chapter 11 Latin America Systemic Scleroderma Treatment Analysis and Forecast
11.1 Introduction
11.2 Latin America Systemic Scleroderma Treatment Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Systemic Scleroderma Treatment Market Size Forecast by Drug Class
11.6.1 Endothelin Receptor Antagonist
11.6.2 Immunosuppressors
11.6.3 Prostacyclin Analogues
11.6.4 PDE-5 Inhibitors
11.7 Basis Point Share (BPS) Analysis by Drug Class
11.8 Absolute $ Opportunity Assessment by Drug Class
11.9 Market Attractiveness Analysis by Drug Class
Chapter 12 Middle East & Africa (MEA) Systemic Scleroderma Treatment Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Systemic Scleroderma Treatment Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Systemic Scleroderma Treatment Market Size Forecast by Drug Class
12.6.1 Endothelin Receptor Antagonist
12.6.2 Immunosuppressors
12.6.3 Prostacyclin Analogues
12.6.4 PDE-5 Inhibitors
12.7 Basis Point Share (BPS) Analysis by Drug Class
12.8 Absolute $ Opportunity Assessment by Drug Class
12.9 Market Attractiveness Analysis by Drug Class
Chapter 13 Competition Landscape
13.1 Systemic Scleroderma Treatment Market: Competitive Dashboard
13.2 Global Systemic Scleroderma Treatment Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Novartis AG
13.3.2 Gilead Sciences Inc
13.3.3 GlaxoSmithKline plc
13.3.4 Boehringer Ingelheim International GmbH
13.3.5 Pfizer Inc
13.3.6 Bayer AG
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Scleroderma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Scleroderma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Scleroderma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Scleroderma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Scleroderma Treatment Market Size & Forecast, 2018-2028
4.5.1 Systemic Scleroderma Treatment Market Size and Y-o-Y Growth
4.5.2 Systemic Scleroderma Treatment Market Absolute $ Opportunity
Chapter 5 Global Systemic Scleroderma Treatment Market Analysis and Forecast by Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug Class
5.1.2 Basis Point Share (BPS) Analysis by Drug Class
5.1.3 Absolute $ Opportunity Assessment by Drug Class
5.2 Systemic Scleroderma Treatment Market Size Forecast by Drug Class
5.2.1 Endothelin Receptor Antagonist
5.2.2 Immunosuppressors
5.2.3 Prostacyclin Analogues
5.2.4 PDE-5 Inhibitors
5.3 Market Attractiveness Analysis by Drug Class
Chapter 6 Global Systemic Scleroderma Treatment Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Systemic Scleroderma Treatment Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Systemic Scleroderma Treatment Analysis and Forecast
8.1 Introduction
8.2 North America Systemic Scleroderma Treatment Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Systemic Scleroderma Treatment Market Size Forecast by Drug Class
8.6.1 Endothelin Receptor Antagonist
8.6.2 Immunosuppressors
8.6.3 Prostacyclin Analogues
8.6.4 PDE-5 Inhibitors
8.7 Basis Point Share (BPS) Analysis by Drug Class
8.8 Absolute $ Opportunity Assessment by Drug Class
8.9 Market Attractiveness Analysis by Drug Class
Chapter 9 Europe Systemic Scleroderma Treatment Analysis and Forecast
9.1 Introduction
9.2 Europe Systemic Scleroderma Treatment Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Systemic Scleroderma Treatment Market Size Forecast by Drug Class
9.6.1 Endothelin Receptor Antagonist
9.6.2 Immunosuppressors
9.6.3 Prostacyclin Analogues
9.6.4 PDE-5 Inhibitors
9.7 Basis Point Share (BPS) Analysis by Drug Class
9.8 Absolute $ Opportunity Assessment by Drug Class
9.9 Market Attractiveness Analysis by Drug Class
Chapter 10 Asia Pacific Systemic Scleroderma Treatment Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Systemic Scleroderma Treatment Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Systemic Scleroderma Treatment Market Size Forecast by Drug Class
10.6.1 Endothelin Receptor Antagonist
10.6.2 Immunosuppressors
10.6.3 Prostacyclin Analogues
10.6.4 PDE-5 Inhibitors
10.7 Basis Point Share (BPS) Analysis by Drug Class
10.8 Absolute $ Opportunity Assessment by Drug Class
10.9 Market Attractiveness Analysis by Drug Class
Chapter 11 Latin America Systemic Scleroderma Treatment Analysis and Forecast
11.1 Introduction
11.2 Latin America Systemic Scleroderma Treatment Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Systemic Scleroderma Treatment Market Size Forecast by Drug Class
11.6.1 Endothelin Receptor Antagonist
11.6.2 Immunosuppressors
11.6.3 Prostacyclin Analogues
11.6.4 PDE-5 Inhibitors
11.7 Basis Point Share (BPS) Analysis by Drug Class
11.8 Absolute $ Opportunity Assessment by Drug Class
11.9 Market Attractiveness Analysis by Drug Class
Chapter 12 Middle East & Africa (MEA) Systemic Scleroderma Treatment Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Systemic Scleroderma Treatment Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Systemic Scleroderma Treatment Market Size Forecast by Drug Class
12.6.1 Endothelin Receptor Antagonist
12.6.2 Immunosuppressors
12.6.3 Prostacyclin Analogues
12.6.4 PDE-5 Inhibitors
12.7 Basis Point Share (BPS) Analysis by Drug Class
12.8 Absolute $ Opportunity Assessment by Drug Class
12.9 Market Attractiveness Analysis by Drug Class
Chapter 13 Competition Landscape
13.1 Systemic Scleroderma Treatment Market: Competitive Dashboard
13.2 Global Systemic Scleroderma Treatment Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Novartis AG
13.3.2 Gilead Sciences Inc
13.3.3 GlaxoSmithKline plc
13.3.4 Boehringer Ingelheim International GmbH
13.3.5 Pfizer Inc
13.3.6 Bayer AG
Segments Covered in the Report
The global Systemic Scleroderma Treatment market has been segmented based on
By Drug Class
The global Systemic Scleroderma Treatment market has been segmented based on
By Drug Class
- Endothelin Receptor Antagonist
- Immunosuppressors
- Prostacyclin Analogues
- PDE-5 Inhibitors
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Novartis AG
- Gilead Sciences Inc
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Pfizer Inc
- Bayer AG
Our Clients
Related Reports
Some other reports from this category!
